- Home
- THCH vs QNCX Comparison
THCH vs QNCX Comparison
Compare THCH & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- QNCX
- Stock Information
- Founded
- THCH 2018
- QNCX 2012
- Country
- THCH China
- QNCX United States
- Employees
- THCH N/A
- QNCX N/A
- Industry
- THCH Blank Checks
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- QNCX Health Care
- Exchange
- THCH Nasdaq
- QNCX Nasdaq
- Market Cap
- THCH 84.8M
- QNCX 90.8M
- IPO Year
- THCH N/A
- QNCX 2019
- Fundamental
- Price
- THCH $2.60
- QNCX $1.69
- Analyst Decision
- THCH
- QNCX Strong Buy
- Analyst Count
- THCH 0
- QNCX 6
- Target Price
- THCH N/A
- QNCX $8.00
- AVG Volume (30 Days)
- THCH 11.8K
- QNCX 216.9K
- Earning Date
- THCH 08-28-2025
- QNCX 08-11-2025
- Dividend Yield
- THCH N/A
- QNCX N/A
- EPS Growth
- THCH N/A
- QNCX N/A
- EPS
- THCH N/A
- QNCX N/A
- Revenue
- THCH $187,384,526.00
- QNCX N/A
- Revenue This Year
- THCH N/A
- QNCX N/A
- Revenue Next Year
- THCH N/A
- QNCX N/A
- P/E Ratio
- THCH N/A
- QNCX N/A
- Revenue Growth
- THCH N/A
- QNCX N/A
- 52 Week Low
- THCH $1.95
- QNCX $0.51
- 52 Week High
- THCH $5.15
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- THCH 40.71
- QNCX 50.81
- Support Level
- THCH $2.49
- QNCX $1.53
- Resistance Level
- THCH $2.90
- QNCX $1.93
- Average True Range (ATR)
- THCH 0.26
- QNCX 0.14
- MACD
- THCH -0.02
- QNCX -0.01
- Stochastic Oscillator
- THCH 65.66
- QNCX 40.00
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.